SQI Diagnostics (SQI Diagnostics) Momentum Rank : 0 (As of May. 24, 2024)

View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics Momentum Rank?

SQI Diagnostics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

SQI Diagnostics Momentum Rank Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SQI Diagnostics (SQI Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

36 Meteor Drive, Toronto, ON, CAN, M9W 1A4

Website

https://www.sqidiagnostics.com

SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.